stockchase picture

Compiling comments that experts make about stocks while on public TV.

Company Index

List by Company Name

List by Symbol

Abbott Labs Stock Symbol: ABT-N

Last Price Recorded: $41.9000 on 2014-09-30 01:14:01

Globe 200 day average
Google Discussions (view only)
yahoo discussion
Bloomberg
Date Signal Expert Opinion Price
2014-09-17 TOP PICK Brian Acker, CA

His model price is $48.91, a 14% upside. Saw that they are going to spin off another company, the gift that keeps on giving. He loves large-cap drug companies. Yield of 2.02%.


Price:
$43.380
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH on US$
Owned:
Yes
2014-08-29 COMMENT Jennifer Radman

Doesn’t follow this one too closely. Recent reports indicate they are doing a lot of things to restart their growth.


Price:
$42.240
Subject:
US LARGE
Bias:
OPTIMISTIC
Owned:
No
2014-07-08 PAST TOP PICK Christine Poole

(Top Pick July 9/13, Up 20.37%) Prefers to stay with this part of the business after the spin out.  This is where the growth is.  They have branded generics which are a growth area in emerging markets.  The just made an acquisition to increase presence in Latin America where pharma should double in the next 5 years.


Price:
$41.050
Subject:
NORTH AMERICAN - LARGE
Bias:
OPTIMISTIC
Owned:
Yes
2014-04-09 DON'T BUY Stan Wong

This one has outperformed the health care sector over the last few years.  Sees a 15% growth rate on the dividend, but it is low compared to others.  Prefers PFE-N.


Price:
$37.630
Subject:
NORTH AMERICAN - LARGE & ETFs
Bias:
SELECTIVE
Owned:
No
2014-02-18 BUY Stuart Hinshelwood

Growth in large-cap pharmaceutical business is fairly anaemic. There are not a lot of great growth prospects. What he does like about this company is that they have a medical technology business, a nutritionals business as well as a traditional pharmaceutical business i.e. all the components of the healthcare sector. Feels there is some growth from an earnings perspective. (See Top Picks.)


Price:
$38.930
Subject:
US EQUITIES
Bias:
CAUTIOUS
Owned:
Yes
2014-02-07 BUY Michael Bowman

Is this a good time to get into health care stocks and what would you recommend? Likes Abbott Labs (ABT-N) very much. Spun off their pharmaceutical R&D business about 2 years ago and split themselves up into 4 different divisions. If looking at global healthcare companies, you can’t go wrong with something like Johnson & Johnson (JNJ-N). Products are cheap and they can easily raise costs. Also, likes Medtronics (MDT-N) which is a device manufacturer.


Price:
$37.180
Subject:
NORTH AMERICAN - LARGE & ETFs
Bias:
BULLISH
Owned:
Unknown
2014-02-04 PAST TOP PICK Christine Poole

(A Top Pick Feb 12/13. Up 7.44%.) Still likes this. Likes their branded pharmaceuticals division. Also, have diagnostics and nutritionals. Company increased their dividend by quite a large amount last quarter. Yield of about 2.5%. Trading at an attractive multiple.


Price:
$36.250
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH
Owned:
Yes
2014-01-29 DON'T BUY Gordon Reid

Has really been falling. Results were a little mixed. Management was quite cautious and said the 2nd half was going to be a challenging time, partly because of difficult comparisons and partly because of the stronger US$. He just doesn’t see a catalyst and the price is a little too high for him.


Price:
$35.850
Subject:
US EQUITIES
Bias:
OPTIMISTIC
Owned:
No
2014-01-02 BUY Gordon Reid

A good stable company. Sold his holdings when they spun off their pharmaceutical division. They are now left with medical devices, nutritional business and their diagnostic business. Have a wonderful record of growing dividends over the years. Very steady and he feels it is underappreciated.


Price:
$38.230
Subject:
US EQUITIES
Bias:
OPTIMISTIC
Owned:
No
2013-12-23 COMMENT Barry Schwartz

Sold his holdings a few months ago in order to look for other opportunities. Valuations are a little too excessive for him. He prefers to buy in the 12-13 times earnings range. Doesn’t see growth in this one.


Price:
$38.440
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH
Owned:
No
2013-12-09 TOP PICK Gavin Graham

Spun off drug side.  It is medical devices and has been one of the most consistent growers over the last decade.  Reasonably priced, 2.5% yield.


Price:
$37.200
Subject:
GLOBAL & NORTH AMERICAN LARGE
Bias:
BULLISH
Owned:
Yes
2013-11-29 PAST TOP PICK Brian Acker, CA

(A Top Pick Nov 26/12. Up 24.63%.) There was a spin out of Abbvie (ABBV-N) from this company


Price:
$38.190
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH
Owned:
No
2013-11-01 TOP PICK Stuart Hinshelwood

Bought this because he was looking to increase his exposure to healthcare. Not that expensive. Nice diverse portfolio. Good exposure, both in North America and outside. Could be $42 over 12 months.


Price:
$36.960
Subject:
US EQUITIES
Bias:
BULLISH
Owned:
Yes
2013-10-30 PAST TOP PICK Mohsin Bashir

(A Top Pick Nov 19/12. Up 25.37%.) Spun off their branded pharmaceutical business last year and he offloaded the AbVie (ABBV-N) component and kept this part that was more focused on medical devices and nutritions. Still likes. Increased their dividend by 57%. Most recent quarter showed that they had made 2 acquisitions on the medical devices side in cataract surgery equipment. 3.2% dividend yield.


Price:
$36.940
Subject:
NORTH AMERICAN - LARGE
Bias:
OPTIMISTIC
Owned:
Yes
2013-10-29 TOP PICK Christine Poole

Adult and infant nutritionals.  Generics, very emerging market focused, diversified.  Good earnings growth going forward.  Very shareholder friendly.  Increasing dividend should attract more shareholders. 


Price:
$37.280
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH
Owned:
Yes
2013-10-10 PAST TOP PICK David Burrows

(Top Pick Oct 11/12, Up 2.37%) Did well with Abvie as well.  He sold ABT.


Price:
$33.640
Subject:
NORTH AMERICAN - LARGE
Bias:
SELECTIVE
Owned:
No
2013-10-04 HOLD Gordon Reid

Sold his holdings before the spinoff of their pharmaceutical side into AbbVie (ABBV-N). They are left with the nutritional, diagnostics and medical devices. Trading at about 14 or 15 times earnings. Growing at 11%-13% per year. Very, very stable company and a great core position in your portfolio.


Price:
$33.560
Subject:
US EQUITIES
Bias:
OPTIMISTIC
Owned:
No
2013-09-19 TOP PICK Stuart Hinshelwood

Diversified healthcare company. Recently spun off their pharmaceutical business. Has some decent growth over the next couple of years. Thinks it can get to $42 over a 12-18 time period.


Price:
$35.340
Subject:
US EQUITIES
Bias:
CAUTIOUS
Owned:
Yes
2013-09-18 PAST TOP PICK Hap (Robert) Sneddon FCSI

(A Top Pick Sept 4/12. Up 13.65%.) He would like to add to his holdings when he gets the opportunity.


Price:
$35.650
Subject:
TECHNICAL ANALYSIS & MACRO STRATEGY
Bias:
NEUTRAL
Owned:
Yes
2013-07-29 TOP PICK Hap (Robert) Sneddon FCSI

Just moved up stop loss to $34.90 (200 day moving average).  They are in the right space.  Nutritional component looks to be just in the beginning of a long term uptrend.


Price:
$36.740
Subject:
TECHNICAL ANALYSIS
Bias:
SELECTIVE
Owned:
Yes
2013-07-09 TOP PICK Christine Poole

Spun off their branded pharmaceutical business last year so now they have 40% in emerging markets and aiming to take closer to 50% over the next couple of years. Have some nutritional products along with their stents. Likes the product pipeline. Playing the increased demand for healthcare products in emerging markets through their branded generics. Continuing to see improved margins. Very attractive entry point. Yield of 1.6%.


Price:
$34.740
Subject:
NORTH AMERICAN - LARGE
Bias:
UNKNOWN
Owned:
Yes
2013-05-31 BUY Gavin Graham

One of the better ways to play pharmaceuticals. Amongst the big Pharmas it is one of the few that actually held up through the big selloff of the patent expiries in the mid-2000. Has a yield of about 2%.


Price:
$36.670
Subject:
NORTH AMERICAN/GLOBAL
Bias:
UNKNOWN
Owned:
Yes
2013-05-09 PAST TOP PICK David Burrows

(Top Pick May 17/12, Up 24.24%) He stayed with this and not the spin-out.  This is about the best performing part of the market this year.  Good dividend growth and very strong balance sheets. 


Price:
$36.180
Subject:
NORTH AMERICAN - LARGE
Bias:
SELECTIVE
Owned:
Yes
2013-04-15 PAST TOP PICK Gavin Graham

(A Top Pick March 15/12. Up 33.59%.) Excellent stock that has done really well. Dividend yield.


Price:
$36.130
Subject:
GLOBAL
Bias:
OPTIMISTIC
Owned:
Yes
2013-04-09 BUY Christine Poole

Split off into 2 companies. This one and Abbvie (ABBV-N). Sold her holdings just before the split and wanted to get back in to this one, which was their pharmaceutical side. The other was too reliant on one drug. This is in nutrition, medical devices and branded generics. Have very big emerging-market exposure. Thinks there is big growth in branded generics. Dividend of just under 2%. Her target is high $30’s-$40 in one year.


Price:
$36.660
Subject:
NORTH AMERICAN - LARGE
Bias:
OPTIMISTIC
Owned:
Yes
2013-03-07 BUY Patrick Horan

Just initiated 3.6% dividend.  Does like it.  They may put growth back into business model or you have an activist shareholder that puts them up for sale.  If stock stays flat you will collect the divided.


Price:
$34.430
Subject:
NORTH AMERICAN
Bias:
BULL
Owned:
Yes
2013-02-26 COMMENT Barry Schwartz

Split into 2 companies, this one and Abbvie (ABBV-N).He is not sold entirely on the split although he continues to hold both. On this one you get the nutritionals, some pharmaceuticals and medical devices. Valuation is not as attractive as it was before the split.


Price:
$34.060
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH
Owned:
Yes
2013-02-25 BUY Chyanne Fickes

She sold ABv.  But ABT-N has a very good basic business.  Doesn’t understand why they don’t pay more dividend (1.6%) and thinks they may increase it soon. 


Price:
$34.270
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
Yes
2013-02-12 TOP PICK Christine Poole

Diversified. Have nutritionals, diagnostics (nice solid business), branded generics and medical devices where they have the leading drug eluting stents. 40% of sales are coming from high-growth emerging markets. Room for margin expansion. 1.64% dividend.


Price:
$34.300
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
Yes
2013-02-05 COMMENT John O'Connell, CFA

(Market Call Minute.) There is a spinoff coming on a restructuring, so be careful about tax implications. When it spins off, buy the medical device manufacturer.


Price:
$33.840
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
Unknown
Showing 1 to 30 of 83 entries
First Previous 1 2 3 Next Last

No Comments.


You must be logged in to comment.